Compare RCUS & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | IRTC |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2018 | 2016 |
| Metric | RCUS | IRTC |
|---|---|---|
| Price | $28.53 | $109.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $31.90 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 1.3M | 558.1K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | N/A | ★ N/A |
| Revenue | $247,000,000.00 | ★ $747,138,000.00 |
| Revenue This Year | N/A | $19.60 |
| Revenue Next Year | $45.62 | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $8.84 | $100.85 |
| 52 Week High | $31.74 | $210.01 |
| Indicator | RCUS | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 42.72 |
| Support Level | $20.20 | $101.30 |
| Resistance Level | $28.72 | $121.88 |
| Average True Range (ATR) | 1.33 | 5.08 |
| MACD | -0.16 | -1.32 |
| Stochastic Oscillator | 50.83 | 15.50 |
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.